Proton therapy (PT) is a promising development in radiation oncology, with the potential to further improve outcomes for patients with squamous cell carcinoma of the head and neck (HNSCC). By utilizing the finite range of protons, healthy tissue can be spared from beam exit doses that would otherwise be irradiated with photon-based treatments. Current evidence on PT for HNSCC is limited to comparative dosimetric analyses and retrospective single-institution series. As a consequence, the recognized indications for the reimbursement of PT remain scarce in most countries. Nevertheless, approximately 100 PT centers are in operation worldwide, and initial experiences for HNSCC are being reported. This review aims to summarize the results of the early clinical experience with PT for HNSCC and the challenges that are currently faced.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179360 | PMC |
| http://dx.doi.org/10.3390/cancers14112587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer outcomes and cardiopulmonary toxicities for black patients with breast cancer treated with proton therapy.
JNCI Cancer Spectr
December 2024
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.
Background: Black women have a 40% higher breast cancer (BC) mortality rate than White women and are at a higher risk of acquiring cardiovascular disease. Proton therapy (PT) can be used to mitigate cardiac radiation exposure; however, PT remains a scarce resource in the United States. We report on the cardiovascular profiles of patients undergoing PT to determine the potential benefit of PT for Black women when compared to non-Black patients.
View Article and Find Full Text PDFPediatric diffuse intrinsic pontine gliomas- a prospective observational study from a tertiary care neurosurgical center.
Childs Nerv Syst
December 2024
Department Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, 560029, India.
Introduction: Diffuse intrinsic pontine glioma (DIPG) in children comprises 80% of brainstem gliomas. In 2021, 5th edition of WHO CNS tumor classification defined H3K27M altered diffuse midline gliomas (DMGs) which replaced this entity. Lesion location precludes resection and the only current option available is radiotherapy.
View Article and Find Full Text PDFPARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy.
Sci Rep
December 2024
Division of Radiation Oncology, Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aggressive breast cancers often fail or acquire resistance to radiotherapy. To develop new strategies to improve the outcome of aggressive breast cancer patients, we studied how PARP inhibition radiosensitizes breast cancer models to proton therapy, which is a radiotherapy modality that generates more DNA damage in the tumor than standard radiotherapy using photons. Two human BRCA1-mutated breast cancer cell lines and their isogenic BRCA1-recovered pairs were treated with a PARP inhibitor and irradiated with photons or protons.
View Article and Find Full Text PDFHealth Utility of Pain Response Versus Nonresponse to Palliative Radiation Therapy for Symptomatic Bone Metastases: Analyses Based on Real-World Data from 26 Centers.
J Palliat Med
December 2024
Department of Radiation Oncology, Saitama Medical center, Saitama, Japan.
Utility values of responders and nonresponders are essential inputs in cost-effectiveness studies of radiation therapy for painful bone metastases but, to our knowledge, they have not been reported separately. We sought to determine the utility values of responders and nonresponders using data from a prospective observational study on bone metastases. The original prospective observational study was conducted at 26 centers in Japan.
View Article and Find Full Text PDFCorrigendum: DiffuseRT: predicting likely anatomical deformations of patients undergoing radiotherapy (2024 69 155016).
Phys Med Biol
December 2024
Paul Scherrer Institute, Center for Proton Therapy, Villigen, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!